Cuproptosis is a recently discovered regulated cell death mechanism that differs from known cell death pathways, showing significant potential in tumor therapy. However, precise delivery of copper (Cu) ions to the tumor site and optimizing their therapeutic efficacy pose significant challenges. In the current study, we have developed a novel Cu-based chemotherapeutic prodrug and photosensitizer coordination polymer for synergistic therapy combining photothermal enhancement with apoptosis-cuproptosis. After internalization by cancer cells, the photothermal effect increases intracellular glutathione depletion and reactive oxygen species production, triggering the release of chemotherapeutic agents camptothecin and doxorubicin and promoting tumor cell apoptosis. Additionally, the presence of Cu2+/Cu+ triggers cuproptosis, leading to a synergistic anti-tumor effect combining apoptosis and cuproptosis. Our findings offer another perspective on potential cancer treatment through the apoptosis-cuproptosis axis and present a novel approach for designing nanomedicine based on cuproptosis.
Read full abstract